Turkish Version of The Upper Limb Hypermobility Assessment Tool

Turkish Version of The Upper Limb Hypermobility Assessment Tool : Reliability and Validity

Hypermobility is more than normal joint laxity, mobility, and range of motion. It is characterized by increased laxity and fragility of connective tissues. Symptoms from hypermobility can begin at any age and affect women more than men. People are at higher risk than other people. It is stated that hypermobility is an important factor in orthopedic injuries and diseases. Individuals with hypermobility have more frequent orthopedic complaints and the problems are usually idiopathic and chronic. Studies have reported that proprioception and musculoskeletal reflex function may be affected independently of symptoms in hypermobile individuals. Therefore, evaluating hypermobility is very important in preventing hypermobility-related problems and injuries and developing appropriate treatment methods. Although the Beighton score is the most commonly used scoring method to determine hypermobility, it may be insufficient to determine hypermobility of the upper extremities. The Upper Limb Hypermobility Assessment Tool (ULHAT) has been reported to be one of the most appropriate scoring methods for assessing upper extremity hypermobility in the literature. The aim of this study is to adapt ULHAT to Turkish and measure its validity and reliability.

Study Overview

• Status: Completed
• Conditions: Hypermobility, Joint
• Intervention / Treatment: Other: Turkish validity and reliability

• Study Type: Observational
• Enrollment (Actual): 100

Contacts and Locations

Study Locations

• Turkey
  • Kutahya, Turkey
    • Kütahya Health Science University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 35 years (ADULT)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

• Sampling Method: Probability Sample

Study Population

- The study will be carried out by young adults and adults in the Kutahya Health Science University

Description

Inclusion Criteria:

• Healthy volunteers
• Aged between 18 to 35

Exclusion Criteria:

• Using assistive devices or orthoses for the upper extremity
• Surgery history of the upper extremity
• Pain located on the upper extremity in the last 6 months
• Previous trauma that might restrict normal range of motion.
• Having degenerative or inflamatuar disease

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The Upper Limb Hypermobility Assessment Tool (ULHAT)	The ULHAT was designed to test the mobility of many joints of the upper limb in multiple planes of motion. These tests include passive physiological, passive accessory and active range of motion. The ULHAT is performed on both upper limbs, each providing a score to a maximum of 12.	15 minutes
The Beighton Score	The Beighton Score is a set of manoeuvres used as the standard method of assessment for Generalised Joint Hypermobility. The Beighton score arbitrarily investigates the presence of hyperlaxity (yes = 1, no = 0) at both wrists, the fifth metacarpo-phalangeal joints, elbows, knee joints, and the lumbosacral spine. The items are summed and yield a Beighton score ranging from 0 to 9 points.	5 minutes

Collaborators and Investigators

• Sponsor: Kutahya Health Sciences University

Study record dates

Study Major Dates

• Study Start (ACTUAL): August 19, 2022
• Primary Completion (ACTUAL): September 22, 2022
• Study Completion (ACTUAL): October 28, 2022

Study Registration Dates

• First Submitted: June 22, 2022
• First Submitted That Met QC Criteria: June 22, 2022
• First Posted (ACTUAL): June 28, 2022

Study Record Updates

• Last Update Posted (ACTUAL): November 7, 2022
• Last Update Submitted That Met QC Criteria: November 4, 2022
• Last Verified: November 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Joint Diseases; Musculoskeletal Diseases; Joint Instability
• Other Study ID Numbers: ULHAT Study

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No